- Trials with a EudraCT protocol (225)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
225 result(s) found for: Pulse oximetry.
Displaying page 1 of 12.
EudraCT Number: 2018-000065-37 | Sponsor Protocol Number: DOSA_Protocol | Start Date*: 2019-01-30 | ||||||||||||||||
Sponsor Name:University of Oxford | ||||||||||||||||||
Full Title: Randomised controlled trial of nasal decongestants versus placebo to prolong treatment free periods from continuous positive airway pressure therapy in mild to moderate obstructive sleep apnoea | ||||||||||||||||||
Medical condition: Obstructive Sleep Apnoea Syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Temporarily Halted) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-005594-29 | Sponsor Protocol Number: Moli1901-010 | Start Date*: 2006-10-31 |
Sponsor Name:AOP Orphan Pharmaceuticals AG | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis | ||
Medical condition: Cystic Fibrosis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-002585-32 | Sponsor Protocol Number: Mpp01 | Start Date*: 2017-11-15 |
Sponsor Name:Infektionskliniken Danderyds sjukhus AB | ||
Full Title: A randomised, multicentre, controlled trial to study the duration of supplemental oxygen treatment in adults with Mycoplasma pneumoniae pneumonia treated with betamethasone in addition to antibiotics | ||
Medical condition: Mycoplasma pneumoniae pneumonia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-003843-28 | Sponsor Protocol Number: STH13565 | Start Date*: 2005-03-18 |
Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | ||
Full Title: The acute effects of testosterone administration in patients with pulmonary hypertension | ||
Medical condition: Pulmonary Hypertension | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-004344-30 | Sponsor Protocol Number: Moli1901-010A | Start Date*: 2005-10-31 |
Sponsor Name:AOP Orphan Pharmaceuticals AG | ||
Full Title: An Evaluation of the Safety and Tolerability of Multiple Dose Regimens of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis and Stable Lung Disease | ||
Medical condition: Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10,000 children. In cystic fibrosis chloride transport across the respiratory epithelium... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-020471-23 | Sponsor Protocol Number: OTR3001 | Start Date*: 2011-05-31 | |||||||||||
Sponsor Name:Purdue Pharma L.P. | |||||||||||||
Full Title: An Open-label, Multicentre Study of the Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children from Ages 6 to 16 Years Old, Inclusive, with Moderate... | |||||||||||||
Medical condition: Opioid tolerant paediatric patients with moderate to severe malignant and/or nonmalignant pain requiring opioid therapy. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) HU (Completed) SK (Completed) DE (Completed) FI (Completed) ES (Completed) EE (Completed) BE (Completed) GR (Prematurely Ended) PL (Completed) SE (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000559-35 | Sponsor Protocol Number: 0 | Start Date*: 2022-07-14 |
Sponsor Name:None | ||
Full Title: COMPLICATIONS AND DEGREE OF TOLERANCE OF THE ADMINISTRATION OF LOCAL ANESTHESIA IN DIAGNOSTIC / THERAPEUTIC THORACOCENTESIS PROCEDURES | ||
Medical condition: There is no consensus about the most appropriate local anesthetic, and 1% mepicavain and 2% lidocaine uses can be postulated indistinctly. This project was born with the intention of highlighting t... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001587-35 | Sponsor Protocol Number: Feline01 | Start Date*: 2014-07-31 |
Sponsor Name:Erasmus Medical Centre, Department of Anesthesiology | ||
Full Title: Dexmedetomidine in awake implantation of neuromodulative systems. | ||
Medical condition: Awake implantation of a neuromodulative system. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-018233-21 | Sponsor Protocol Number: WEC 0910 | Start Date*: 2010-03-31 |
Sponsor Name:Leiden University Medical Centre | ||
Full Title: Modeling the respiratory effects of subanesthetic doses of propofol under closed-loop or non-steady-state conditions without and with a remifentanil background infusion in healthy volunteers. | ||
Medical condition: This study is performed in healthy volunteers. The study is aimed at investigating the effect of propofol and remifentanil-propofol interaction on breathing in awake, non-artificially ventilated vo... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003455-11 | Sponsor Protocol Number: VX19-445-115 | Start Date*: 2020-01-17 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3b Open-label Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Cystic Fibrosis Subjects | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-005110-22 | Sponsor Protocol Number: SNT-I-018 | Start Date*: 2017-11-20 |
Sponsor Name:Santhera Pharmaceuticals (Switzerland) Ltd | ||
Full Title: Phase-Ib/IIa study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of orally inhaled multiple doses of POL6014 in patients with Cystic Fibrosis | ||
Medical condition: Cystic fibrosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001950-41 | Sponsor Protocol Number: P01911 | Start Date*: 2015-06-30 | |||||||||||
Sponsor Name:Papworth Hospital NHS Foundation Trust - Research and Development Department | |||||||||||||
Full Title: The effect of acute intravenous (iv) morphine administration on Sleep Disordered Breathing (SDB) in patients with moderate Obstructive Sleep Apnoea (OSA): A paired design trial | |||||||||||||
Medical condition: Obstructive Sleep Apnoea (OSA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006693-24 | Sponsor Protocol Number: Moli1901-010B | Start Date*: 2007-05-09 | |||||||||||
Sponsor Name:AOP Orphan Pharmaceuticals AG | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis | |||||||||||||
Medical condition: Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10.000 children. In cystic fibrosis chloride transport across the respiratory epithelium... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) CZ (Completed) FR (Completed) DE (Completed) HU (Completed) SE (Completed) ES (Completed) PL (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001437-12 | Sponsor Protocol Number: COVID-19_ASS | Start Date*: 2020-04-09 | |||||||||||
Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) | |||||||||||||
Full Title: Random, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugs | |||||||||||||
Medical condition: Severe COVID-19 pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002774-64 | Sponsor Protocol Number: HP 3.1 | Start Date*: 2007-12-04 |
Sponsor Name:Deutsches Herzzentrum Berlin, Kompetenznetz Angeborene Herzfehler | ||
Full Title: Therapy of PAH – Treatment with Sildenafil in Eisenmenger Patients | ||
Medical condition: Patients with pre-existing congenital heart disease may develop Eisenmenger physiology (EP), characterized by development of pulmonary arterial hypertension and intracardiac right to left shunt. Th... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000964-33 | Sponsor Protocol Number: Feline02 | Start Date*: 2015-09-17 |
Sponsor Name:Erasmus Medical Center, Department of Anesthesiology | ||
Full Title: Dexmedetomidine versus propofol in awake implantation of a neuromodulative system. | ||
Medical condition: Awake implantation of a neuromodulative system. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-000202-75 | Sponsor Protocol Number: P.Sitsen.03 | Start Date*: 2007-06-15 |
Sponsor Name:Leids Universitair Medisch Centrum | ||
Full Title: A comparison of the efficacy of levobupivacaine 0,125%, ropivacaine 0,125% and ropivacaine 0,2%, all combined with sufentanil 0.5 micrograms/mL, in patient-controlled epidural analgesia after hyste... | ||
Medical condition: Primary Objective •to compare the analgesic efficacy of levobupivacaine and ropivacaine in patient-controlled epidural analgesia, as assessed by the number of requests for epidural bolus injections... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002667-42 | Sponsor Protocol Number: ABR53999 | Start Date*: 2015-09-09 |
Sponsor Name:AMC | ||
Full Title: Sedation with propofol TCI during ERCP: Is the combination with esketamine more effective and safer than with alfentanil (SPEKA): A randomized controlled multicentre trial | ||
Medical condition: Patients undergoing ERCPs under propofol sedation combined with ketamine or alfentanil given by trained anesthesia nurse. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000822-24 | Sponsor Protocol Number: VP-C21-005 | Start Date*: 2020-07-06 | |||||||||||
Sponsor Name:Vicore Pharma AB | |||||||||||||
Full Title: A Phase 2, Multi-Centre, Open-Label, Single-Arm Trial Investigating the Safety, Efficacy and Pharmacokinetics of C21 in Subjects with Idiopathic Pulmonary Fibrosis | |||||||||||||
Medical condition: Idiopathic Pulmonary Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002835-76 | Sponsor Protocol Number: VX18-445-104 | Start Date*: 2019-10-29 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation... | |||||||||||||
Medical condition: Cystic fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IE (Completed) DE (Completed) DK (Completed) FR (Completed) BE (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
